June 1995
Volume 36, Issue 7
Free
Articles  |   June 1995
Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
Author Affiliations
  • H Ghiasi
    Department of Ophthalmology Research, Cedars-Sinai Medical Center Research Institute, Los Angeles, CA 90048, USA.
  • S Bahri
    Department of Ophthalmology Research, Cedars-Sinai Medical Center Research Institute, Los Angeles, CA 90048, USA.
  • A B Nesburn
    Department of Ophthalmology Research, Cedars-Sinai Medical Center Research Institute, Los Angeles, CA 90048, USA.
  • S L Wechsler
    Department of Ophthalmology Research, Cedars-Sinai Medical Center Research Institute, Los Angeles, CA 90048, USA.
Investigative Ophthalmology & Visual Science June 1995, Vol.36, 1352-1360. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H Ghiasi, S Bahri, A B Nesburn, S L Wechsler; Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.. Invest. Ophthalmol. Vis. Sci. 1995;36(7):1352-1360.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To compare the efficacy of each of seven expressed herpes simplex virus 1 (HSV-1) glycoproteins as vaccines to protect against ocular disease after primary ocular HSV-1 infection. METHODS: Mice were vaccinated three times with equal amounts of each of seven individually expressed HSV-1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI) and then ocularly challenged with McKrae, a corneal disease-producing strain of HSV-1. Viral clearance from the eye, blepharitis, keratitis, and neovascularization were determined at various times after infection. RESULTS: Mice vaccinated with gD or gB had the best protection against eye disease. Vaccination with gI, gC, or gE produced moderate protection against eye disease. Vaccination with gG produced less protection, and vaccination with gH produced no apparent protection against eye disease. CONCLUSIONS: These results suggest that when used as vaccines, different HSV-1 glycoproteins provide different levels of protection against HSV-1-induced eye disease. Based on comparison with the authors' previously published results, the ability of each glycoprotein to protect against eye disease correlated with the ability of the glycoprotein to induce high serum neutralizing antibody titers and killer cell activity. Results suggest that the effectiveness of these seven glycoproteins in protecting against eye disease can be ranked as follows: gD > gB > gI > (gC = gE) > gG > gH.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×